LEUPLIN SR FOR INJECTION
Leuplin Sr For Injection Adverse Events Reported to the FDA Over Time
How are Leuplin Sr For Injection adverse event reports trending over time?
This graph shows volume of adverse events submitted to the FDA by quarter for Leuplin Sr For Injection, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Leuplin Sr For Injection is flagged as the suspect drug causing the adverse event.
Most Common Leuplin Sr For Injection Adverse Events Reported to the FDA
What are the most common Leuplin Sr For Injection adverse events reported to the FDA?
| Prostate Cancer | 105 (6.19%) |
| Prostate Cancer Stage Iv | 55 (3.24%) |
| Cerebral Infarction | 44 (2.59%) |
| Interstitial Lung Disease | 44 (2.59%) |
| Pneumonia | 37 (2.18%) |
| Hepatic Function Abnormal | 35 (2.06%) |
| Injection Site Induration | 34 (2%) |
| Lung Neoplasm Malignant | 33 (1.95%) |
| Colon Cancer | 25 (1.47%) |
| Constipation | 25 (1.47%) |
| Cardiac Failure | 23 (1.36%) |
 Show More |
Share/Embed Graph Export Data
This graph shows the top adverse events submitted to the FDA for Leuplin Sr For Injection, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Leuplin Sr For Injection is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.
Adverse Event Categories for Leuplin Sr For Injection
What are the most common Leuplin Sr For Injection adverse events reported to the FDA?
| Reproductive Neoplasms Male Maligna... | 163 (9.61%) |
| Infections - Pathogen Unspecified | 90 (5.31%) |
| Gastrointestinal Neoplasms Malignan... | 83 (4.89%) |
| Administration Site Reactions | 73 (4.3%) |
| Central Nervous System Vascular | 66 (3.89%) |
| Lower Respiratory Tract Disorders | 63 (3.71%) |
| Urinary Tract Signs | 57 (3.36%) |
| Hepatic And Hepatobiliary | 53 (3.13%) |
| Metastases | 49 (2.89%) |
| Hepatobiliary | 48 (2.83%) |
| Coronary Artery | 41 (2.42%) |
| Show More |
Share/Embed Graph Export Data
This graph shows the top categories of adverse events submitted to the FDA for Leuplin Sr For Injection, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Leuplin Sr For Injection is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.
Common Uses of Leuplin Sr For Injection According to Those Reporting Adverse Events
Why are people taking Leuplin Sr For Injection, according to those reporting adverse events to the FDA?
| Prostate Cancer Stage Iv | 247 |
| Prostate Cancer Stage Ii | 173 |
| Prostate Cancer | 108 |
| Prostate Cancer Stage Iii | 94 |
| Breast Cancer | 19 |
| Prostate Cancer Stage I | 9 |
| Show More |
Leuplin Sr For Injection Case Reports
What Leuplin Sr For Injection safety concerns are being reported by doctors and researchers in the medical literature?
About Results
This report contains aggregated drug side effects and adverse events for Leuplin Sr For Injection. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.
DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.
DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.
Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.
Comments
Share your experience with Leuplin Sr For Injection.